GlpBio

C-type natriuretic peptide (1-22) (human, rat, swine)

目录号: GC12034纯度: >98%
COASDSData Sheet

C 型钠尿肽 (1-22)（人、大鼠、猪）（C-type natriuretic peptide (1-22) (human, rat, swine) ）是一种存在于血浆和脑脊液中的内源性肽。

C-type natriuretic peptide (1-22) (human, rat, swine)
Cas No.: 127869-51-6
规格价格库存数量操作
500µg¥1,502.00现货
1
电话: 400-920-5774Email: sales@glpbio.cn

文献被引

本产品暂无引用记录;以下为 GlpBio 产品在 Nature / Cell / Science 等顶刊的客户引用样例
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

产品描述 Description

C-type natriuretic peptide (1-22) (human, rat, swine) is an endogenous peptide found in plasma and cerebrospinal fluid[2]. C-type natriuretic peptide (CNP) is a member of the natriuretic peptide (NP) family [3]. It is also a potent, endothelial-derived relaxant and growth-inhibitory factor[6]. C-type natriuretic peptide (1-22) (human, rat, swine) is an agonist for the natriuretic peptide receptor NPR2 (NPRB) and has an affinity for NPR3 (NPRC). C-type natriuretic peptide (1-22) (human, rat, swine) can inhibit L-type calcium current in cardiomyocytes, has anti-proliferation effect in cardiac fibroblasts in vitro, and can promote vasodilation[7].

C-type natriuretic peptide (1-22) (human, rat, swine) increased cGMP production in CHO cells expressing human NPR-B in a concentration-dependent manner[1].

C-type natriuretic peptide (1-22) (human, rat, swine) could be transported across the vascular wall and reach NPR-B in peripheral tissues[1]. exogenous CNP(1-22) improved endochondral ossification and accelerated bone growth in mice after constant intravenous infusion at a large dose only[4]. I.c.v. administration of C-type natriuretic peptide (1-22) (human, rat, swine) in a dose of 2 nmol induced an increase in the severity of picrotoxin-kindled convulsions 24 and 48 hrs after application of the peptide[5].

References:
[1]. Morozumi N, Yotsumoto T, et,al. ASB20123: A novel C-type natriuretic peptide derivative for treatment of growth failure and dwarfism. PLoS One. 2019 Feb 22;14(2):e0212680. doi: 10.1371/journal.pone.0212680. PMID: 30794654; PMCID: PMC6386482.
[2]. Minamino N, Makino Y, et,al.Characterization of immunoreactive human C-type natriuretic peptide in brain and heart. Biochem Biophys Res Commun. 1991 Aug 30;179(1):535-42. doi: 10.1016/0006-291x(91)91404-z. PMID: 1831979.
[3]. Potter LR, Yoder AR, et,al. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol. 2009;(191):341-66. doi: 10.1007/978-3-540-68964-5_15. PMID: 19089336; PMCID: PMC4855512.
[4]. Yasoda A, Kitamura H, et,al. Systemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias. Endocrinology. 2009 Jul;150(7):3138-44. doi: 10.1210/en.2008-1676. Epub 2009 Mar 12. PMID: 19282381; PMCID: PMC2703521.
[5]. Mazarati AM, HalÁszi E, et,al. ANP(1-28), BNP(1-32) and CNP(1-22) increase the severity of picrotoxin-kindled seizure syndrome in rats. Life Sci. 1993;52(3):PL19-24. doi: 10.1016/0024-3205(93)90227-t. PMID: 8423706.
[6]. Buckley MG, Jenkins GH, et,al. Circulating C-type natriuretic peptide is increased in orthotopic cardiac transplant recipients and associated with cardiac allograft vasculopathy. Clin Sci (Lond). 2000 Nov;99(5):467-72. PMID: 11052928.
[7]. Pejchalova K, Krejci P, et,al.C-natriuretic peptide: an important regulator of cartilage. Mol Genet Metab. 2007 Nov;92(3):210-5. doi: 10.1016/j.ymgme.2007.06.014. Epub 2007 Aug 6. PMID: 17681481.

C 型钠尿肽 (1-22)（人、大鼠、猪）（C-type natriuretic peptide (1-22) (human, rat, swine) ）是一种存在于血浆和脑脊液中的内源性肽[2]。 C型利钠肽(CNP)是利钠肽(NP)家族[3]的一员。它还是一种有效的内皮衍生松弛剂和生长抑制因子[6]。 C-type natriuretic peptide (1-22) (human, rat, swine) 是利钠肽受体 NPR2 (NPRB) 的激动剂，对 NPR3 (NPRC) 具有亲和力。 C型钠尿肽（1-22）（人、大鼠、猪）可抑制心肌细胞L型钙电流，在体外对心肌成纤维细胞具有抗增殖作用，并可促进血管舒张[7].

C 型钠尿肽 (1-22)（人、大鼠、猪）以浓度依赖性方式增加表达人 NPR-B 的 CHO 细胞中 cGMP 的产生[1] .

C型钠尿肽（1-22）（人、大鼠、猪）可跨血管壁转运，到达外周组织的NPR-B[1] 。外源性 CNP(1-22) 仅在大剂量持续静脉输注后改善软骨内骨化并加速骨骼生长[4]。 I.c.v.施用 2 nmol 剂量的 C 型利钠肽 (1-22)（人、大鼠、猪）可在施用该肽后 24 小时和 48 小时诱导印防己毒素引发的惊厥的严重程度增加[5 ].

实验参考方法 Experimental Reference Method

Cell experiment [1]:

Cell lines

CHO cells

Preparation Method

To evaluate the human NPR (hNPR) agonist activities of the test compounds(C-type natriuretic peptide (1-22) (human, rat, swine)), Using Chinese hamster ovarian (CHO) cells stably expressing hNPR-A or hNPR-B. Each compound was added to the cells in duplicate and incubated for 15 min. Cells were lysed.

Reaction Conditions

0.01-1000nM C-type natriuretic peptide (1-22) (human, rat, swine)for 15 min

Applications

C-type natriuretic peptide (1-22) (human, rat, swine) increased cGMP production in CHO cells expressing human NPR-B in a concentration-dependent manner.
Animal experiment [1]:

Animal models

Sprague Dawley (SD) rats

Preparation Method

Rats received C-type natriuretic peptide (1-22) (human, rat, swine) or ASB20123 by intravenous (iv) injection into the tail vein or subcutaneous (sc) injection into the back.

Dosage form

C-type natriuretic peptide (1-22) (human, rat, swine) iv (20 nmol/kg) or sc (50 nmol/kg)

Applications

C-type natriuretic peptide (1-22) (human, rat, swine) could be transported across the vascular wall and reach NPR-B in peripheral tissues.

References:

[1].Morozumi N, Yotsumoto T, Yamaki A, Yoshikiyo K, Yoshida S, Nakamura R, Jindo T, Furuya M, Maeda H, Minamitake Y, Kangawa K. ASB20123: A novel C-type natriuretic peptide derivative for treatment of growth failure and dwarfism. PLoS One. 2019 Feb 22;14(2):e0212680. doi: 10.1371/journal.pone.0212680. PMID: 30794654; PMCID: PMC6386482.

产品文档 Product Documents

Purity:>98%
COASDSData Sheet

化学性质Chemical Properties

CAS 号
127869-51-6
化学名
(4R,5E,8Z,10S,11Z,14Z,16S,17Z,19S,20Z,22S,23E,26Z,28S,29Z,31S,32E,34S,35Z,37S,38E,40S,41Z,43S,44Z,47Z,49S,50Z,52R)-52-((Z)-((3Z,5S,6Z,8S,9Z,11S,12Z)-14-amino-5-(4-aminobutyl)-1,4,7,10,13-pentahydroxy-8-(hydroxymethyl)-11-isobutyl-3,6,9,12-tetraazatetradec
SMILES
CC[C@]([C@@]1([H])/C(O)=N/C/C(O)=N\[C@@](/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/C/C(O)=N/[C@@](/C(O)=N/C/C(O)=N\[C@@](C(O)=O)([H])CSSC[C@@](/N=C(O)/C/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/CN)([H])CC(C)C)([H])CO)([H])CCCCN)([H])/C(O)=N/[C@@](/C(O)=N/C
分子式
C93H157N27O28S3
分子量
2197.61 g/mol
溶解性
H<sub>2</sub>O : 50 mg/mL (22.75 mM; adjust pH to 3 with 0.5%CH3COOH)
保存条件
Desiccate at -20&deg;C
General tips
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
为了提高溶解度，请将管子加热至 37°C，然后在超声波浴中震荡一段时间。
Shipping Condition
评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备 RT，或根据请求配备蓝冰。

计算工具摩尔浓度 / 稀释 / 分子量 / 单位换算 / 体内配方 / 溶解度

g/mol